A MULTICENTER, OPEN-LABEL PHASE 1/1B DOSE-FINDING, SAFETY, AND PHARMACOKINETIC STUDY OF MBRC-101, AN ANTI-EPHA5 MONOMETHYL AURISTATIN E(MMAE) ANTIBODY DRUG CONJUGATE, IN ADVANCED REFRACTORY SOLID TUMORS
Contact:
NCT Number:
Protocol:
AAAV4204
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I
The purpose of this research is to determine the dose and dosing regimens of an investigational drug, MBRC-101, that are well tolerated, as well as to evaluate its safety in patients with advanced or metastatic solid tumors that have already received conventional therapy. MBRC-101 is not an approved treatment anywhere in the world. “Investigational” means that the drug has not been approved by any government authority responsible for the regulation of new medicines, such as the U.S. Food and Drug Administration (FDA). This is the first time MBRC-101 is being tested in humans.
Are you Eligible? (Inclusion Criteria)
- 18 years of age or older at the time of informed consent. 2. Life expectancy greater than or equal to 3 months as assessed by the investigator. 3. Does not have major surgery within 28 days prior to first dose of study drug.
Specialty Area(s)
Breast Cancer, Colon and Rectal Cancer, Esophageal Cancer, Gynecologic Cancers, Cervical Cancer, Ovarian Cancer, Uterine (Endometrial) Cancer, Kidney Cancer/Adrenal Cancer, Lung cancer, Pancreatic Cancer, Prostate Cancer, Stomach Cancer, Testicular Cancer, Thyroid Cancer
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
